ProTrials Global Ltd Establishes New Subsidiary in UK
News Jan 23, 2012
ProTrials Research, Inc., the contract research company (CRO), announced the creation of a wholly owned subsidiary to help meet its sponsors' increasing needs for multi-national, multi-site clinical trials. Based in the United Kingdom, ProTrials Global Limited will help manage ongoing clinical trials in Italy, Spain and the U.K., and will be responsible for additional growth in the European arena.
Gillian Reid, the company's newly appointed director of business operations, Europe, will manage ProTrials Global Limited. With more than 25 years of clinical research experience, Reid is highly regarded for her past work with companies such as Charles River Laboratories, Inveresk Research, Napp Laboratories and Merck Sharp & Dohme. Most recently, she was the director of global key accounts for Chiltern International UK. She holds a bachelors of science degree in biochemistry with honors from Edinburgh University.
"We've found the right person in Gillian to help us take this important step forward in our commitment to always bring senior level involvement, high customer service and impeccable data quality to clinical research," said Jodi Andrews, co-founder and CEO of ProTrials. "With our increasing business in Europe, we needed a skilled senior manager who could manage our projects there as well as further develop new clients and our global employee pool -- all while helping us to maintain our high standards as we grow."
Late last year, industry research firm Frost & Sullivan projected that the global CRO market had resumed its upward growth trajectory and was on target to reach revenues of $43.09 billion by 2017. The demand for global clinical trials is being driven by potential access to a diverse and large untapped patient population.
"With ProTrials Global Limited based in the United Kingdom, we are in a stronger position to help sponsors simultaneously conduct clinical trials in North America and Europe, and to guide them in the different complexities for conducting clinical research abroad," Andrews said.
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE